Juan Antonio Páez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan Antonio Páez has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Nuria Eugenia Campillo
Centro de Investigaciones Biológicas Margarita Salas (CIB Margarita Salas−CSIC)
6 shared publications Pedro González-Naranjo
Instituto de Química Médica (CSIC)
3 shared publicationsAngela Guerra
Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
2 shared publicationsAngeles Martin-Requero
Centro de Investigaciones Biológicas Margarita Salas (CSIC)
2 shared publicationsConcepción Pérez
Instituto de Quimica Medica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
2 shared publications- Concepción Pérez
IQM-CSIC
2 shared publications
Latest Publications
- Open Access
- 11 March 2025
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 127, 251-268
Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model
- 11 March 2025
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 127, 251-268
Open AccessTargeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model
- Open Access
- 21 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
AI-driven de-novo design and development of non-toxic DYRK1A inhibitors
(DYRK1A) plays a key role in various diseases, including DYRK1A syndrome, cancer, diabetes, and neurodegenerative disorders such as Alzheimer’s disease (AD), making it a compelling therapeutic target. This work integrates multiple Artificial Intelligence (AI) methods, including predictive models and generative algorithms, to design non-toxic DYRK1A inhibitors. A dual-target drug discovery framework is constructed by combining AI-driven approaches with classical techniques. An ensemble Quantitative Structure-Activity Relationship (QSAR) model predicts compound affinities, while Directed Message Passing Neural Networks (DMPNN) assess toxicity. In the generative phase, a Hierarchical Graph Generation (HGG) model facilitates the design of potential inhibitors, which are further refined through docking studies, synthesized, and experimentally validated. This approach led to the identification of the pyrazolyl-1H-pyrrolo[2,3-b]pyridine 1 as a potent DYRK1A inhibitor, prompting the synthesis of a novel derivative series. Enzymatic assays confirmed nanomolar-level inhibitory activity, while ORAC assays and LPS-induced pro-inflammatory response evaluations in BV2 microglial cells demonstrated antioxidant and anti-inflammatory properties. Overall, these compounds exhibit strong DYRK1A inhibition alongside promising pharmacological effects.
- 21 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAI-driven de-novo design and development of non-toxic DYRK1A inhibitors
(DYRK1A) plays a key role in various diseases, including DYRK1A syndrome, cancer, diabetes, and neurodegenerative disorders such as Alzheimer’s disease (AD), making it a compelling therapeutic target. This work integrates multiple Artificial Intelligence (AI) methods, including predictive models and generative algorithms, to design non-toxic DYRK1A inhibitors. A dual-target drug discovery framework is constructed by combining AI-driven approaches with classical techniques. An ensemble Quantitative Structure-Activity Relationship (QSAR) model predicts compound affinities, while Directed Message Passing Neural Networks (DMPNN) assess toxicity. In the generative phase, a Hierarchical Graph Generation (HGG) model facilitates the design of potential inhibitors, which are further refined through docking studies, synthesized, and experimentally validated. This approach led to the identification of the pyrazolyl-1H-pyrrolo[2,3-b]pyridine 1 as a potent DYRK1A inhibitor, prompting the synthesis of a novel derivative series. Enzymatic assays confirmed nanomolar-level inhibitory activity, while ORAC assays and LPS-induced pro-inflammatory response evaluations in BV2 microglial cells demonstrated antioxidant and anti-inflammatory properties. Overall, these compounds exhibit strong DYRK1A inhibition alongside promising pharmacological effects.
- Open Access
- 1 September 2022
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 2348-2356
Multitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors
Multitarget drugs are a promising therapeutic approach against Alzheimer’s disease. In this work, a new family of 5-substituted indazole derivatives with a multitarget profile including cholinesterase and BACE1 inhibition is described. Thus, the synthesis and evaluation of a new class of 5-substituted indazoles has been performed. Pharmacological evaluation includes in vitro inhibitory assays on AChE/BuChE and BACE1 enzymes. Also, the corresponding competition studies on BuChE were carried out. Additionally, antioxidant properties have been calculated from ORAC assays. Furthermore, studies of anti-inflammatory properties on Raw 264.7 cells and neuroprotective effects in human neuroblastoma SH-SY5Y cells have been performed. The results of pharmacological tests have shown that some of these 5-substituted indazole derivatives 1–4 and 6 behave as AChE/BuChE and BACE1 inhibitors, simultaneously. In addition, some indazole derivatives showed anti-inflammatory (3, 6) and neuroprotective (1–4 and 6) effects against Aβ-induced cell death in human neuroblastoma SH-SY5Y cells with antioxidant properties.
- 1 September 2022
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 2348-2356
Open AccessMultitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors
Multitarget drugs are a promising therapeutic approach against Alzheimer’s disease. In this work, a new family of 5-substituted indazole derivatives with a multitarget profile including cholinesterase and BACE1 inhibition is described. Thus, the synthesis and evaluation of a new class of 5-substituted indazoles has been performed. Pharmacological evaluation includes in vitro inhibitory assays on AChE/BuChE and BACE1 enzymes. Also, the corresponding competition studies on BuChE were carried out. Additionally, antioxidant properties have been calculated from ORAC assays. Furthermore, studies of anti-inflammatory properties on Raw 264.7 cells and neuroprotective effects in human neuroblastoma SH-SY5Y cells have been performed. The results of pharmacological tests have shown that some of these 5-substituted indazole derivatives 1–4 and 6 behave as AChE/BuChE and BACE1 inhibitors, simultaneously. In addition, some indazole derivatives showed anti-inflammatory (3, 6) and neuroprotective (1–4 and 6) effects against Aβ-induced cell death in human neuroblastoma SH-SY5Y cells with antioxidant properties.
- 1 October 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (19) , 115672
New cannabinoid receptor antagonists as pharmacological tool
- 1 October 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (19) , 115672
New cannabinoid receptor antagonists as pharmacological tool
- 1 March 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 166, 90-107
Indazolylketones as new multitarget cannabinoid drugs
- 1 March 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 166, 90-107
Indazolylketones as new multitarget cannabinoid drugs
- 1 March 2013
- Vol. 9 (1) , 130-140
Artificial Neural Networks Based on CODES Descriptors in Pharmacology: Identification of Novel Trypanocidal Drugs against Chagas Disease
A supervised artificial neural network model has been developed for the accurate prediction of the anti-T. cruzi activity of heterogeneous series of compounds. A representative set of 72 compounds of wide structural diversity was chosen in this study. The definition of the molecules was achieved from an unsupervised neural network using a new methodology, CODES program. This program codifies each molecule into a set of numerical parameters taking into account exclusively its chemical structure. The final model shows high average accuracy of 84% (training performance) and predictability of 77% (external validation performance) for the 4:4:1 architecture net with different training set and external prediction test. This approach using CODES methodology represents a useful tool for the prediction of pharmacological properties. CODES (c) is available free of charge for academic institutions.
- 1 March 2013
- Vol. 9 (1) , 130-140
Artificial Neural Networks Based on CODES Descriptors in Pharmacology: Identification of Novel Trypanocidal Drugs against Chagas Disease
A supervised artificial neural network model has been developed for the accurate prediction of the anti-T. cruzi activity of heterogeneous series of compounds. A representative set of 72 compounds of wide structural diversity was chosen in this study. The definition of the molecules was achieved from an unsupervised neural network using a new methodology, CODES program. This program codifies each molecule into a set of numerical parameters taking into account exclusively its chemical structure. The final model shows high average accuracy of 84% (training performance) and predictability of 77% (external validation performance) for the 4:4:1 architecture net with different training set and external prediction test. This approach using CODES methodology represents a useful tool for the prediction of pharmacological properties. CODES (c) is available free of charge for academic institutions.